GENVOYA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Genvoya, and what generic alternatives are available?
Genvoya is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are eleven patents protecting this drug.
This drug has five hundred and five patent family members in fifty-four countries.
The generic ingredient in GENVOYA is cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate profile page.
DrugPatentWatch® Generic Entry Outlook for Genvoya
Genvoya was eligible for patent challenges on November 5, 2019.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 6, 2033. This may change due to patent challenges or generic licensing.
There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for GENVOYA
International Patents: | 505 |
US Patents: | 11 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 19 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for GENVOYA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for GENVOYA |
What excipients (inactive ingredients) are in GENVOYA? | GENVOYA excipients list |
DailyMed Link: | GENVOYA at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for GENVOYA
Generic Entry Date for GENVOYA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for GENVOYA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Canadian Institutes of Health Research (CIHR) | Phase 2 |
St. Michael's Hospital, Toronto | Phase 2 |
CIHR Canadian HIV Trials Network | Phase 2 |
Pharmacology for GENVOYA
Anatomical Therapeutic Chemical (ATC) Classes for GENVOYA
US Patents and Regulatory Information for GENVOYA
GENVOYA is protected by eleven US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of GENVOYA is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting GENVOYA
Use of solid carrier particles to improve the processability of a pharmaceutical agent
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
4-oxoquinoline compound and use thereof as pharmaceutical agent
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Prodrugs of phosphonate nucleotide analogues
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Stable crystal of 4-oxoquinoline compound
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Prodrugs of phosphonate nucoleotide analogues
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HIV INFECTION
Modulators of pharmacokinetic properties of therapeutics
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Combination therapy
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Tenofovir alafenamide hemifumarate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Stable crystal of 4-oxoquinoline compound
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Tenofovir alafenamide hemifumarate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Modulators of pharmacokinetic properties of therapeutics
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GENVOYA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | See Plans and Pricing | See Plans and Pricing |
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | See Plans and Pricing | See Plans and Pricing |
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | See Plans and Pricing | See Plans and Pricing |
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | See Plans and Pricing | See Plans and Pricing |
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | See Plans and Pricing | See Plans and Pricing |
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for GENVOYA
When does loss-of-exclusivity occur for GENVOYA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
African Regional IP Organization (ARIPO)
Patent: 89
Estimated Expiration: See Plans and Pricing
Patent: 50
Estimated Expiration: See Plans and Pricing
Argentina
Patent: 5369
Estimated Expiration: See Plans and Pricing
Australia
Patent: 09242451
Estimated Expiration: See Plans and Pricing
Patent: 10210598
Estimated Expiration: See Plans and Pricing
Patent: 14221210
Estimated Expiration: See Plans and Pricing
Patent: 15200637
Estimated Expiration: See Plans and Pricing
Patent: 16250470
Estimated Expiration: See Plans and Pricing
Patent: 17201473
Estimated Expiration: See Plans and Pricing
Patent: 18267573
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 0911871
Estimated Expiration: See Plans and Pricing
Patent: 1008664
Estimated Expiration: See Plans and Pricing
Canada
Patent: 20856
Estimated Expiration: See Plans and Pricing
Patent: 50521
Estimated Expiration: See Plans and Pricing
Chile
Patent: 11001885
Estimated Expiration: See Plans and Pricing
China
Patent: 2123700
Estimated Expiration: See Plans and Pricing
Patent: 2307573
Estimated Expiration: See Plans and Pricing
Patent: 3479584
Estimated Expiration: See Plans and Pricing
Patent: 4940937
Estimated Expiration: See Plans and Pricing
Colombia
Patent: 21225
Estimated Expiration: See Plans and Pricing
Patent: 00187
Estimated Expiration: See Plans and Pricing
Croatia
Patent: 0151009
Estimated Expiration: See Plans and Pricing
Patent: 0151357
Estimated Expiration: See Plans and Pricing
Cyprus
Patent: 16852
Estimated Expiration: See Plans and Pricing
Patent: 17067
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 96633
Estimated Expiration: See Plans and Pricing
Patent: 93485
Estimated Expiration: See Plans and Pricing
Ecuador
Patent: 10010636
Estimated Expiration: See Plans and Pricing
Patent: 11011307
Estimated Expiration: See Plans and Pricing
Eurasian Patent Organization
Patent: 1313
Estimated Expiration: See Plans and Pricing
Patent: 2950
Estimated Expiration: See Plans and Pricing
Patent: 0123
Estimated Expiration: See Plans and Pricing
Patent: 1071173
Estimated Expiration: See Plans and Pricing
Patent: 1190125
Estimated Expiration: See Plans and Pricing
Patent: 1491658
Estimated Expiration: See Plans and Pricing
Patent: 1591353
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 96633
Estimated Expiration: See Plans and Pricing
Patent: 93485
Estimated Expiration: See Plans and Pricing
Patent: 06032
Estimated Expiration: See Plans and Pricing
Hong Kong
Patent: 53670
Estimated Expiration: See Plans and Pricing
Patent: 64737
Estimated Expiration: See Plans and Pricing
Patent: 15679
Estimated Expiration: See Plans and Pricing
Hungary
Patent: 25822
Estimated Expiration: See Plans and Pricing
Patent: 26380
Estimated Expiration: See Plans and Pricing
Israel
Patent: 8614
Estimated Expiration: See Plans and Pricing
Patent: 4227
Estimated Expiration: See Plans and Pricing
Patent: 7417
Estimated Expiration: See Plans and Pricing
Japan
Patent: 11242
Estimated Expiration: See Plans and Pricing
Patent: 22213
Estimated Expiration: See Plans and Pricing
Patent: 11927
Estimated Expiration: See Plans and Pricing
Patent: 25171
Estimated Expiration: See Plans and Pricing
Patent: 11522790
Estimated Expiration: See Plans and Pricing
Patent: 12517432
Estimated Expiration: See Plans and Pricing
Patent: 14012741
Estimated Expiration: See Plans and Pricing
Patent: 14221845
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 2377
Estimated Expiration: See Plans and Pricing
Patent: 10011963
Estimated Expiration: See Plans and Pricing
Patent: 11008289
Estimated Expiration: See Plans and Pricing
New Zealand
Patent: 8978
Estimated Expiration: See Plans and Pricing
Patent: 4214
Estimated Expiration: See Plans and Pricing
Peru
Patent: 110994
Estimated Expiration: See Plans and Pricing
Poland
Patent: 96633
Estimated Expiration: See Plans and Pricing
Patent: 93485
Estimated Expiration: See Plans and Pricing
Portugal
Patent: 96633
Estimated Expiration: See Plans and Pricing
Patent: 93485
Estimated Expiration: See Plans and Pricing
San Marino
Patent: 01500266
Estimated Expiration: See Plans and Pricing
Singapore
Patent: 3544
Estimated Expiration: See Plans and Pricing
Patent: 0618
Estimated Expiration: See Plans and Pricing
Patent: 14007744
Estimated Expiration: See Plans and Pricing
Patent: 201609006W
Estimated Expiration: See Plans and Pricing
Patent: 201706215U
Estimated Expiration: See Plans and Pricing
Slovenia
Patent: 96633
Estimated Expiration: See Plans and Pricing
Patent: 93485
Estimated Expiration: See Plans and Pricing
South Africa
Patent: 1008007
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 1645759
Estimated Expiration: See Plans and Pricing
Patent: 1659971
Estimated Expiration: See Plans and Pricing
Patent: 1738325
Estimated Expiration: See Plans and Pricing
Patent: 1784647
Estimated Expiration: See Plans and Pricing
Patent: 110015581
Estimated Expiration: See Plans and Pricing
Patent: 110122729
Estimated Expiration: See Plans and Pricing
Patent: 160093100
Estimated Expiration: See Plans and Pricing
Patent: 160114728
Estimated Expiration: See Plans and Pricing
Spain
Patent: 48886
Estimated Expiration: See Plans and Pricing
Patent: 53897
Estimated Expiration: See Plans and Pricing
Taiwan
Patent: 44367
Estimated Expiration: See Plans and Pricing
Patent: 1040142
Estimated Expiration: See Plans and Pricing
Ukraine
Patent: 1193
Estimated Expiration: See Plans and Pricing
Patent: 3224
Estimated Expiration: See Plans and Pricing
Uruguay
Patent: 424
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering GENVOYA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2005225039 | See Plans and Pricing | |
Slovenia | 1636190 | See Plans and Pricing | |
New Zealand | 594214 | TABLETS COMPRISING COBICISTAT, ELVITEGRAVIR, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE FOR COMBINATION THERAPY | See Plans and Pricing |
Japan | 5063554 | See Plans and Pricing | |
Taiwan | I248928 | See Plans and Pricing | |
South Korea | 100188357 | See Plans and Pricing | |
South Korea | 20080064909 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for GENVOYA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1301519 | C01301519/01 | Switzerland | See Plans and Pricing | PRODUCT NAME: TENOFOVIRALAFENAMID; REGISTRATION NO/DATE: SWISSMEDIC AUTHORISATION 65793 01.09.2016 |
1564210 | C01564210/01 | Switzerland | See Plans and Pricing | CHANGE OF ADDRESS OF THE OWNER: JAPAN TOBACCO INC., 1-1, TORANOMON 4-CHOME, MINATO-KU, TOKYO 105-6927, JP |
1301519 | 300803 | Netherlands | See Plans and Pricing | PRODUCT NAME: TENOFOVIRALAFENAMIDE OF EEN ZOUT OF SOLVAAT DAARVAN, MET NAME TENOFOVIRALAFENAMIDEFUMARAAT; NATIONAL REGISTRATION NO/DATE: EU/1/15/1061/002 20151123; FIRST REGISTRATION: EU EU/1/15/1061/001 20151123 |
3150586 | 122020000022 | Germany | See Plans and Pricing | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON, DARUNAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON UND EMTRICITABIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/17/1225 20170921 |
2487163 | 60/2016 | Austria | See Plans and Pricing | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE ATAZANAVIR-SULFAT; REGISTRATION NO/DATE: EU/1/15/1025 (MITTEILUNG) 20150715 |
3150586 | 132020000000055 | Italy | See Plans and Pricing | PRODUCT NAME: COBICISTAT O UN SALE FARMACOLOGICAMENTE ACCETTABILE O UN SOLVATO DELLO STESSO, DARUNAVIR O UN SALE FARMACOLOGICAMENTE ACCETTABILE O UN SOLVATO DELLO STESSO, IN PARTICOLARE DARUNAVIR ETANOLATO, E EMTRICITABINE O UN SALE FARMACOLOGICAMENTE ACCETTABILE O UN SOLVATO DELLO STESSO(SYMTUZA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1225, 20170925 |
2487166 | 93354 | Luxembourg | See Plans and Pricing | PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI ET ALAFENAMIDE DE TENOFOVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE FUMARATE D'ALAFENAMIDE DE TENOFOVIR; AUTHORISATION NUMBER AND DATE: EU/1/15/1061 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |